Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6174353 | 0.95 | SLC18A2 (0.47) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL2603288 | 0.88 | SLC18A2 (0.49) | SLC18A2 | |
| SCHEMBL20419217 | 0.85 | SLC18A2 (0.46) | SLC18A2 | |
| SCHEMBL7250816 | 0.84 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL17114374 | 0.84 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL17114376 | 0.84 | SLC18A2 (0.45) | SLC18A2CYP1A2CYP2D6HIF1A | |
| SCHEMBL13995045 | 0.83 | SLC18A2 (0.50) | SLC18A2 | |
| SCHEMBL2603270 | 0.83 | SLC18A2 (0.50) | SLC18A2 | |
| SCHEMBL7244257 | 0.80 | CHRNB4 (0.46) | SLC18A2 | |
| SCHEMBL9750912 | 0.79 | LMNA (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080565-B2 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-01-22 | — | — | US | disclosed |
| US-7368463-B2 | Substituted 4-amino-1-benzylpiperidine compounds | THERAVANCE, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026954-A1 | Muscarinic receptor antagonists; overactive bladder, irritable bowel syndrome, chronic obstructive pulmonary disease, and asthma | CHRM5, CHRM3, CHRM1 | SLC18A2 1120/4885CYP1A2 380/4885CYP2D6 906/4885 |
| US-20090023777-A1 | Substituted 4-amino-benzylpiperidine compounds | CHRM5, CHRM3, GPR4 | SLC18A2 739/4885CYP1A2 370/4885CYP2D6 689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.